Virginia Sun1, Tracy E Crane2, Samantha D Slack3, Angela Yung4, Sarah Wright3, Stephen Sentovich5, Kurt Melstrom5, Marwan Fakih6, Robert S Krouse7, Cynthia A Thomson3. 1. Department of Population Sciences, City of Hope, Duarte, CA, USA. Electronic address: vsun@coh.org. 2. College of Nursing, University of Arizona, Tucson, AZ, USA; University of Arizona Cancer Center, Tucson, AZ, USA. 3. University of Arizona Cancer Center, Tucson, AZ, USA; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA. 4. University of Arizona Cancer Center, Tucson, AZ, USA. 5. Division of Surgical Oncology, Department of Surgery, City of Hope, Duarte, CA, USA. 6. Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA. 7. Surgical Services, Corporal Michael J. Crescenz Veterans Affairs Medical Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
PURPOSE: Bowel dysfunction is a common, persistent long-term effect of treatment for rectal cancer survivors. Survivors often use dietary modifications to maintain bowel control. There are few evidence-based interventions to guide survivors on appropriate diet modifications for bowel symptom management. The purpose of this paper is to describe the development and design of the Altering Intake, Managing Symptoms (AIMS) intervention to support bowel dysfunction management in rectal cancer survivors. METHODS: The AIMS intervention is a ten-session, telephone-based diet behavior change intervention delivered by trained health coaches. It uses dietary recall, participant-completed food and symptom diaries, and health coaching guided by motivational interviewing to promote bowel symptom management and improved diet quality. Based on the Chronic Care Self-Management Model (CCM), the AIMS Intervention is designed to improve self-efficacy and self-management of bowel symptoms by coaching survivors to appropriately modify their diets through goal setting, self-monitoring, and problem-solving. The intervention targets survivors with stage I-III rectosigmoid colon/rectum cancer who are 6 months post-treatment, 21 years and older, and English-speaking. CONCLUSIONS: The design and development process described in this paper provides an overview and underscores the potential of the AIMS intervention to positively impact the quality of long-term survivorship for rectal cancer survivors. An ongoing pilot study will inform the design and development of future multi-site Phase II and III randomized trials.
PURPOSE:Bowel dysfunction is a common, persistent long-term effect of treatment for rectal cancer survivors. Survivors often use dietary modifications to maintain bowel control. There are few evidence-based interventions to guide survivors on appropriate diet modifications for bowel symptom management. The purpose of this paper is to describe the development and design of the Altering Intake, Managing Symptoms (AIMS) intervention to support bowel dysfunction management in rectal cancer survivors. METHODS: The AIMS intervention is a ten-session, telephone-based diet behavior change intervention delivered by trained health coaches. It uses dietary recall, participant-completed food and symptom diaries, and health coaching guided by motivational interviewing to promote bowel symptom management and improved diet quality. Based on the Chronic Care Self-Management Model (CCM), the AIMS Intervention is designed to improve self-efficacy and self-management of bowel symptoms by coaching survivors to appropriately modify their diets through goal setting, self-monitoring, and problem-solving. The intervention targets survivors with stage I-III rectosigmoid colon/rectum cancer who are 6 months post-treatment, 21 years and older, and English-speaking. CONCLUSIONS: The design and development process described in this paper provides an overview and underscores the potential of the AIMS intervention to positively impact the quality of long-term survivorship for rectal cancer survivors. An ongoing pilot study will inform the design and development of future multi-site Phase II and III randomized trials.
Authors: Susan M Czajkowski; Lynda H Powell; Nancy Adler; Sylvie Naar-King; Kim D Reynolds; Christine M Hunter; Barbara Laraia; Deborah H Olster; Frank M Perna; Janey C Peterson; Elissa Epel; Josephine E Boyington; Mary E Charlson Journal: Health Psychol Date: 2015-02-02 Impact factor: 4.267
Authors: Lisette M Wiltink; Remi A Nout; Jochem R N van der Voort van Zyp; Heleen M Ceha; Marta Fiocco; Elma Meershoek-Klein Kranenbarg; Andreas W K S Marinelli; Cornelis J H van de Velde; Corrie A M Marijnen Journal: Clin Colorectal Cancer Date: 2016-02-13 Impact factor: 4.481
Authors: Lisa J Herrinton; Andrea Altschuler; Carmit K McMullen; Joanna E Bulkley; Mark C Hornbrook; Virginia Sun; Christopher S Wendel; Marcia Grant; Carol M Baldwin; Wendy Demark-Wahnefried; Larissa K F Temple; Robert S Krouse Journal: CA Cancer J Clin Date: 2016-03-21 Impact factor: 508.702
Authors: Lisette M Wiltink; Corrie A M Marijnen; Elma Meershoek-Klein Kranenbarg; Cornelis J H van de Velde; Remi A Nout Journal: Acta Oncol Date: 2015-09-25 Impact factor: 4.089
Authors: Patricio B Lynn; Lindsay A Renfro; Xiomara W Carrero; Qian Shi; Paul L Strombom; Oliver Chow; Julio Garcia-Aguilar Journal: Dis Colon Rectum Date: 2017-05 Impact factor: 4.585
Authors: Jeffrey A Meyerhardt; Pamela B Mangu; Patrick J Flynn; Larissa Korde; Charles L Loprinzi; Bruce D Minsky; Nicholas J Petrelli; Kim Ryan; Deborah H Schrag; Sandra L Wong; Al B Benson Journal: J Clin Oncol Date: 2013-11-12 Impact factor: 44.544
Authors: Virginia Sun; Tracy E Crane; Kathryn B Arnold; Katherine Guthrie; Sarah Freylersythe; Christa Braun-Inglis; Lee Jones; Stacey A Cohen; Mazin Al-Kasspooles; Robert S Krouse; Cynthia A Thomson Journal: Contemp Clin Trials Commun Date: 2021-04-08